| | 718630-59-2 Basic information More.. |
| Product Name: | PHA-793887 | | Synonyms: | 3-Methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]butanamide;PHA-793887;N-(6,6-dimethyl-5-(1-methylpiperidine-4-carbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-methylbutanamide;3-Methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]butanamide PHA-793887;PHA-793887
3-Methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c]pyrazol-3-yl]butanamide;PHA-793887;PHA793887;3-Methyl-N-[1,4,5,6-tetrahydro-6,6-dimethyl-5-[(1-methyl-4-piperidinyl)carbonyl]pyrrolo[3,4-c];PHA-793887 USP/EP/BP | | CAS: | 718630-59-2 | | MF: | C19H31N5O2 | | MW: | 361.48 | | EINECS: | | | Mol File: | 718630-59-2.mol |  |
Use
PHA-793887 is a potent CDK (cyclin-dependent kinase) inhibitor. Recent studies shows that PHA-793887 has promising therapeutic activity against acute leukemias in vitro and in vivo. PHA-793887 was used to successfully modulate E2F transcriptional factor-dependent cell cycle, DNA replication, mitosis and apoptosis related gene in both tumors and skin biopsy from patients with solid tumors.
|
|
718630-59-2
Recommend Suppliers |
|